Cedric  Francois net worth and biography

Cedric Francois Biography and Net Worth

Dr. Francois is a co-founder of our company and has served as a member of our board of directors and as our President and Chief Executive Officer since September 2009. Prior to co-founding our company, Dr. Francois co-founded Potentia Pharmaceuticals, a private biotechnology company, which transacted with Alcon Research Ltd in 2009. Dr. Francois received his MD degree from the University of Leuven in Belgium and his PhD degree in physiology from the University of Louisville. Following postgraduate training in pediatric and transplant surgery, Dr. Francois joined the research team that performed the first successful hand transplantation in Louisville in 1999.

What is Cedric Francois' net worth?

The estimated net worth of Cedric Francois is at least $11.91 million as of March 1st, 2024. Dr. Francois owns 313,662 shares of Apellis Pharmaceuticals stock worth more than $11,912,883 as of July 21st. This net worth evaluation does not reflect any other assets that Dr. Francois may own. Additionally, Dr. Francois receives an annual salary of $1,440,000.00 as CEO at Apellis Pharmaceuticals. Learn More about Cedric Francois' net worth.

How old is Cedric Francois?

Dr. Francois is currently 52 years old. There are 1 older executives and no younger executives at Apellis Pharmaceuticals. Learn More on Cedric Francois' age.

What is Cedric Francois' salary?

As the CEO of Apellis Pharmaceuticals, Inc., Dr. Francois earns $1,440,000.00 per year. Learn More on Cedric Francois' salary.

How do I contact Cedric Francois?

The corporate mailing address for Dr. Francois and other Apellis Pharmaceuticals executives is 100 FIFTH AVENUE, WALTHAM MA, 02451. Apellis Pharmaceuticals can also be reached via phone at (617) 977-5700 and via email at [email protected]. Learn More on Cedric Francois' contact information.

Has Cedric Francois been buying or selling shares of Apellis Pharmaceuticals?

Cedric Francois has not been actively trading shares of Apellis Pharmaceuticals within the last three months. Most recently, Cedric Francois sold 250,000 shares of the business's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $64.11, for a transaction totalling $16,027,500.00. Following the completion of the sale, the chief executive officer now directly owns 313,662 shares of the company's stock, valued at $20,108,870.82. Learn More on Cedric Francois' trading history.

Who are Apellis Pharmaceuticals' active insiders?

Apellis Pharmaceuticals' insider roster includes Caroline Baumal (Insider), Victoria Brown (Insider), James Chopas (CAO), Mark DeLong (SVP), Pascal Deschatelets (Insider), A. Dunlop (Director), Jeffrey Eisele (Insider), Cedric Francois (CEO), Federico Grossi (Insider), Karen Lewis (Insider), Alec Machiels (Director), Nur Nicholson (Insider), Nicole Perry (VP), Lukas Scheibler (Insider), Timothy Sullivan (CFO), Adam Townsend (Insider), and David Watson (General Counsel). Learn More on Apellis Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Apellis Pharmaceuticals?

During the last twelve months, insiders at the sold shares 45 times. They sold a total of 784,074 shares worth more than $41,486,176.07. The most recent insider tranaction occured on June, 21st when Director A. Sinclair Dunlop sold 37,000 shares worth more than $1,451,880.00. Insiders at Apellis Pharmaceuticals own 6.8% of the company. Learn More about insider trades at Apellis Pharmaceuticals.

Information on this page was last updated on 6/21/2024.

Cedric Francois Insider Trading History at Apellis Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2024Sell250,000$64.11$16,027,500.00313,662View SEC Filing Icon  
2/12/2024Sell3,962$67.77$268,504.74313,662View SEC Filing Icon  
1/29/2024Sell2,843$64.14$182,350.02317,624View SEC Filing Icon  
1/22/2024Sell13,431$65.00$873,015.00320,467View SEC Filing Icon  
1/16/2024Sell7,851$66.81$524,525.31333,898View SEC Filing Icon  
11/21/2023Sell5,000$48.80$244,000.00269,655View SEC Filing Icon  
9/1/2023Sell150,000$41.75$6,262,500.00424,655View SEC Filing Icon  
5/16/2023Sell30,000$85.66$2,569,800.00274,655View SEC Filing Icon  
4/18/2023Sell30,000$82.02$2,460,600.00637,601View SEC Filing Icon  
3/21/2023Sell30,000$62.74$1,882,200.001,144,591View SEC Filing Icon  
12/19/2022Sell28,200$52.06$1,468,092.00965,128View SEC Filing Icon  
12/15/2020Sell5,000$52.16$260,800.001,113,079View SEC Filing Icon  
11/16/2020Sell5,000$39.38$196,900.001,078,079View SEC Filing Icon  
10/15/2020Sell5,000$34.46$172,300.001,083,079View SEC Filing Icon  
9/15/2020Sell5,000$30.96$154,800.00
8/20/2020Sell3,457$30.00$103,710.001,093,079View SEC Filing Icon  
8/18/2020Sell1,543$30.00$46,290.001,096,536View SEC Filing Icon  
7/15/2020Sell5,000$32.12$160,600.001,098,079View SEC Filing Icon  
6/15/2020Sell5,000$30.21$151,050.00
11/15/2019Sell5,000$27.82$139,100.00
10/15/2019Sell5,000$27.81$139,050.00
9/16/2019Sell5,000$26.59$132,950.00
8/15/2019Sell10,000$26.80$268,000.00View SEC Filing Icon  
See Full Table

Cedric Francois Buying and Selling Activity at Apellis Pharmaceuticals

This chart shows Cedric Francois's buying and selling at Apellis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Apellis Pharmaceuticals Company Overview

Apellis Pharmaceuticals logo
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Read More

Today's Range

Now: $37.98
Low: $37.32
High: $38.59

50 Day Range

MA: $39.97
Low: $34.98
High: $43.60

2 Week Range

Now: $37.98
Low: $19.83
High: $73.80

Volume

1,000,244 shs

Average Volume

1,542,776 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88